- Home
- GBX vs EWTX Comparison
GBX vs EWTX Comparison
Compare GBX & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBX
- EWTX
- Stock Information
- Founded
- GBX 1974
- EWTX 2017
- Country
- GBX United States
- EWTX United States
- Employees
- GBX N/A
- EWTX N/A
- Industry
- GBX Railroads
- EWTX Biotechnology: Pharmaceutical Preparations
- Sector
- GBX Industrials
- EWTX Health Care
- Exchange
- GBX Nasdaq
- EWTX Nasdaq
- Market Cap
- GBX 1.5B
- EWTX 1.6B
- IPO Year
- GBX N/A
- EWTX 2021
- Fundamental
- Price
- GBX $46.02
- EWTX $15.15
- Analyst Decision
- GBX Hold
- EWTX Buy
- Analyst Count
- GBX 2
- EWTX 10
- Target Price
- GBX $59.50
- EWTX $37.90
- AVG Volume (30 Days)
- GBX 251.9K
- EWTX 750.0K
- Earning Date
- GBX 10-28-2025
- EWTX 11-06-2025
- Dividend Yield
- GBX 2.79%
- EWTX N/A
- EPS Growth
- GBX 88.14
- EWTX N/A
- EPS
- GBX 7.10
- EWTX N/A
- Revenue
- GBX $3,533,700,000.00
- EWTX N/A
- Revenue This Year
- GBX N/A
- EWTX N/A
- Revenue Next Year
- GBX N/A
- EWTX N/A
- P/E Ratio
- GBX $6.47
- EWTX N/A
- Revenue Growth
- GBX 0.70
- EWTX N/A
- 52 Week Low
- GBX $37.77
- EWTX $10.60
- 52 Week High
- GBX $71.06
- EWTX $38.12
- Technical
- Relative Strength Index (RSI)
- GBX 51.44
- EWTX 49.86
- Support Level
- GBX $45.20
- EWTX $14.68
- Resistance Level
- GBX $46.43
- EWTX $15.59
- Average True Range (ATR)
- GBX 1.04
- EWTX 0.83
- MACD
- GBX 0.09
- EWTX -0.07
- Stochastic Oscillator
- GBX 76.23
- EWTX 39.16
About GBX Greenbrier Companies Inc. (The)
Greenbrier Companies Inc designs, manufactures, and markets railroad freight car equipment in North America and Europe, marine barges in North America and provides wheel services, railcar refurbishment, and parts, leasing and other services to the railroad. Its segments include Manufacturing, Maintenance Services and Leasing & Management Services. The company generates a majority of its revenue from the manufacturing segment. Geographically, it derives a majority of its revenue from the United States.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.